Exactech Announces Successful First Surgeries with Truliant® Knee System
May 31 2017 - 9:15AM
Business Wire
Surgeons welcome new design for improved
efficiency and reproducibility
Exactech (Nasdaq: EXAC), a developer and producer of bone and
joint restoration products and biologic solutions for extremities,
knee and hip, is pleased to announce that the first surgeries using
the new Truliant® Knee System were performed yesterday. Truliant,
which recently received 510(k) clearance from the U.S. Food and
Drug Administration, offers a comprehensive portfolio of implants
and instrumentation designed to help surgeons address the remaining
clinical challenges of total knee replacement.
Craig Morrison, MD, of the Southern Joint Replacement Institute
in Nashville, Tenn., and Michael Dayton, MD, from the University of
Colorado in Denver, Colo. were the first surgeons to use the new
knee system. According to Dr. Dayton, “The Truliant system has the
advantage of being very user-friendly from the standpoint of
ergonomic instrumentation. It should allow me to more accurately
size, balance and efficiently perform the surgeries.”
“The Truliant system is intuitive,” Dr. Morrison said. “What I
saw today is that you put the instrument in a surgeon’s hand, and
they know what to do with it right away. I think the competitive
advantage of this system is going to be how easily Truliant
accommodates a surgeon’s preferred workflow.”
Designed with the ultimate surgical experience in mind, the
Truliant Knee System is a high-performance, comprehensive platform
that addresses the clinical challenges in primary and revision
total knee replacement. Leveraging Exactech’s core principles,
Truliant applies advanced design philosophies and surgical
technologies to help surgeons deliver clinical outcomes
reproducibly case after case.
According to Exactech’s Vice President of Knee Marketing Joseph
Pizzurro, “With the number of knee arthroplasty surgeries on the
rise, there is a market and clinical need for a system that offers
enhanced efficiency and overall reproducibility. Based on input
from a wide array of surgeons, Exactech’s design team of engineers
and surgeon consultants converged to develop a modern, fully
comprehensive knee system that offers a broad range of implants,
intuitive instrumentation and computer-assisted technology to
accommodate a variety of surgical approaches and philosophies. We
are thrilled to introduce Truliant to the marketplace.”
Surgeons cite Exactech’s collaborative culture as a key to the
new knee system’s intuitive design. “The people at Exactech are
always leaning forward and engaging the surgeons,” said Ronald
Hillock, MD, an orthopaedic surgeon in Las Vegas, Nev. “They have
been very receptive to feedback, and I’ve always been impressed
with the depth of their interest, from the top down. Everybody is
in tune with designing a product that will give the best outcomes.
It is engrained in their culture and it definitely comes through
the products. Truliant is a prime example.”
Truliant is in pilot launch with a group of U.S. surgeons. Full
market availability is expected in the United States during
2018.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech can be found
at http://www.exac.com.
A current investment profile on Exactech (Nasdaq: EXAC) is
available online at http://www.hawkassociates.com/profile/exac.cfm.
To receive future releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170531005820/en/
Investor contacts:ExactechJody Phillips, 352-377-1140Executive
Vice President of Finance & Chief Financial OfficerorHawk
AssociatesJulie Marshall or Frank Hawkins,
305-451-1888EXAC@hawkassociates.comorMedia
contact:ExactechPriscilla Bennett, 352-377-1140Vice President,
Corporate & Marketing Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Sep 2023 to Sep 2024